Advertisement

Topics

Bristol-Myers Squibb Company (NYSE:BMY) Given a $60.00 Price Target at Piper Jaffray Companies

01:04 EDT 31 Jul 2017 | Topix

The brokerage presently has a "hold" rating on the biopharmaceutical company's stock. Piper Jaffray Companies' price objective indicates a potential upside of 8.56% from the stock's current price.

Original Article: Bristol-Myers Squibb Company (NYSE:BMY) Given a $60.00 Price Target at Piper Jaffray Companies

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb Company (NYSE:BMY) Given a $60.00 Price Target at Piper Jaffray Companies"

Quick Search
Advertisement
 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...